AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37323059
Drug: GSK2831781 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 450 mg IV
Trial: 36088650
Drug: GSK2831781 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 150 mg SC
Trial: 36088650
Drug: GSK2831781 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 450 mg SC
Trial: 33485464
Drug: Nivolumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (3 mg/kg intravenously once every 2 weeks) plus ipilimumab (1 mg/kg intravenously once every 6 weeks) for up to 2 years
Trial: 33485464
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed [500 mg/m2 intravenously] plus cisplatin [75 mg/m2 intravenously] or carboplatin [area under the concentration‐time curve 5 mg/mL per min intravenously]) once every 3 weeks for up to six cycles
Trial: 32811682
Drug: PARP inhibitors
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PARP inhibitors overall
Trial: 33128473
Drug: 1% LT-BOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% LT-BOL cream
Trial: 35397122
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative chemotherapy
Trial: 35923425
Drug: B-EV71 vaccine
RxNorm normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-EV71 vaccine (Older-B group)
Trial: 35923425
Drug: C-EV71 vaccine
RxNorm normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-EV71 vaccine (Older-C group)
Trial: 35923425
Drug: B-EV71 vaccine
RxNorm normalized name: Hepatitis B Vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-EV71 vaccine (Younger-B group)
Trial: 34571023
Drug: CNS stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS stimulants
Trial: 32342857
Drug: 30 ml/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml/kg/day feed increments
Trial: 32342857
Drug: 18 ml/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 ml/kg/day feed increments
Trial: 35299968
Drug: Probiotics (Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, Bifidobacterium animalis subsp. lactis CP-9) administered daily for 6 months along with regular insulin therapy.
Trial: 35299968
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (insulin therapy without probiotics).
Trial: 33235307
Drug: Protonated nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Protonated nicotine (18 mg/mL, medium protonation) e-liquid
Trial: 33235307
Drug: Nicotine benzoate
RxNorm normalized name: nicotine benzoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine benzoate formulation (30 mg/mL nicotine, high protonation)
Trial: 36226244
Drug: MTX and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX and LEF combination therapy
Trial: 34543098
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg daily dose of linezolid
Trial: 34543098
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg daily dose of linezolid
Trial: 33814474
Drug: EMG BF
RxNorm normalized name: BF-844
DrugBank: BF-844 (DB17801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMG BF training combined with conventional physical therapy (n=17)
Trial: 33814474
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy (Control group, n=16)
Trial: 32807615
Drug: One-stage lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage lateral thoracodorsal flap with an implant
Trial: 32807615
Drug: Latissimus dorsi
RxNorm normalized name: Saccharina latissima extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latissimus dorsi reconstruction combined with an implant
Trial: 32880468
Drug: Up-front resection
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up-front resection with adjuvant chemotherapy
Trial: 33047216
Drug: Cemdisiran (50–900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemdisiran (50–900 mg single doses or 100–600 mg repeat doses)
Trial: 33047216
Drug: Cemdisiran (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemdisiran (200 or 400 mg weekly)
Trial: 33047216
Drug: Eculizumab (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab (900 or 1200 mg biweekly)
Trial: 33047216
Drug: Cemdisiran (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemdisiran (600 mg)
Trial: 33047216
Drug: Cemdisiran (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemdisiran (various doses)
Trial: 33394852
Drug: Paxos Scope
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paxos Scope (smartphone-based ophthalmic camera)
Trial: 33885775
Drug: Hydroxychloroquine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (800 mg loading dose, then 400 mg daily for 9 days)
Trial: 33885775
Drug: Lopinavir-ritonavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir-ritonavir (800 mg and 200 mg loading dose every 12 hours, followed by 400 mg and 100 mg every 12 hours for 9 days)
Trial: 33012605
Drug: BK-SE36/CpG (full-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BK-SE36/CpG (full-dose)
Trial: 33012605
Drug: BK-SE36/CpG (half-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BK-SE36/CpG (half-dose)
Trial: 34797597
Drug: Intralesional injection
RxNorm normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injection of tranexamic acid
Trial: 34797597
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Kligman combination drug
Trial: 34548284
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy (mean HbA1c 7.2%)
Trial: 34548284
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (mean HbA1c 9.0%)
Trial: 34548284
Drug: DCCT conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCCT conventional therapy
Trial: 36416841
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2000 international units daily)
Trial: 36161344
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (700 IU) plus Calcium (500 mg) daily for 3 years
Trial: 36161344
Drug: Placebo (double
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (double placebo) daily for 3 years
Trial: 34628916
Drug: Sitting and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitting and lying Liuzijue exercise (LG) for 3 months, 30 minutes twice daily.
Trial: 34628916
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and nursing (CG)
Trial: 35689818
Drug: Oral sulphate
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulphate tablets (OST)
Trial: 33849367
Drug: Dexmedetomidine (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (Group D, 1 μg/kg before, and 0.6 μg/kg/hour during procedure)
Trial: 33849367
Drug: Midazolam (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (Group M, 2 mg before procedure)
Trial: 32960773
Drug: Digital devices
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital devices for information delivery (tablet computers, e-learning platforms, public website)
Trial: 33586513
Drug: G +
RxNorm normalized name: Citracal 250 mg + D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G + chemo
Trial: 35015065
Drug: Written Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written Exposure Therapy (5 weekly sessions)
Trial: 35015065
Drug: Cognitive Processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Processing Therapy (12 twice-weekly sessions)
Trial: 35180287
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise intervention (two daily sessions of moderate-intensity exercises)
Trial: 34164887
Drug: Ato‐Oxy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ato‐Oxy plus zolpidem (10 mg)
Trial: 36251422
Drug: Renin-Angiotensin System
RxNorm normalized name: Renin-angiotensin system inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-Angiotensin System Inhibitors (RASi)
Trial: 36251422
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker or thiazide diuretic (control)
Trial: 34560015
Drug: PXL770 250
RxNorm normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL770 250 mg once daily
Trial: 34560015
Drug: PXL770 250
RxNorm normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL770 250 mg twice daily
Trial: 34560015
Drug: PXL770 500
RxNorm normalized name: PXL770 free acid anhydrous
DrugBank: PXL-770 free acid anhydrous (DB17615)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PXL770 500 mg once daily
Trial: 36314868
Drug: LHF-535 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHF-535 (0.3 mg/kg to 40 mg/kg single ascending dose)
Trial: 36314868
Drug: LHF-535 (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHF-535 (450 mg/day, 900 mg/day, 1,125 mg/day for 14 days, with a loading dose of 2,250 mg for the first dose in the 1,125 mg/day cohort)
Trial: 36031789
Drug: Dolutegravir-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir-based therapy
Trial: 33920232
Drug: AREDS formulation
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AREDS formulation with added DHA, lutein, zeaxanthin, resveratrol, and hydroxytyrosol (intervention group)
Trial: 33920232
Drug: AREDS formulation
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AREDS formulation (control group)
Trial: 34601160
Drug: TXA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA plus topical CSS
Trial: 33823461
Drug: Baseline WMHv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline WMHv (1.62 mL median, IQR 0.66–3.98 mL)
Trial: 32742143
Drug: Group cessation
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cessation intervention plus pharmacotherapy
Trial: 34676656
Drug: Cold atmospheric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold atmospheric plasma (CAP) applied twice a week for six consecutive weeks in addition to standard wound care
Trial: 32450497
Drug: brexpiprazole 2
RxNorm normalized name: brexpiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 2 or 4 mg/day
Trial: 36192924
Drug: Chinese Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Medical Nutrition Therapy (CMNT) diet for T2D patients (5-day low-calorie diet followed by 10 days of habitual eating for 90 days)
Trial: 36192924
Drug: Chinese Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese Medical Nutrition Therapy (CMNT) diet for db/db mice (low-calorie mouse CMNT diet in day 1-4 and ad libitum regular chow for up to 7 days per cycle)
Trial: 36398423
Drug: Dexmedetomidine/remifentanil and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine/remifentanil and low dose sevoflurane anaesthesia
Trial: 33792111
Drug: Sea buckthorn
RxNorm normalized name: sea buckthorn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sea buckthorn cream
Trial: 38576178
Drug: BRV 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRV 50 mg/day
Trial: 36256638
Drug: Counseling message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling message addressing user-centered concerns about self-injection (treatment group)
Trial: 33369937
Drug: NOV03 4
RxNorm normalized name: NOV03
DrugBank: Perfluorohexyloctane (DB17823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOV03 4 times daily (QID)
Trial: 33369937
Drug: NOV03 twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOV03 twice daily (BID)
Trial: 34369566
Drug: Light force
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light force (300 g)
Trial: 34369566
Drug: Heavy force
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy force (500 g)
Trial: 32916236
Drug: Photon radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Photon radiation with chemotherapy
Trial: 32916236
Drug: Proton radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton radiation with chemotherapy
Trial: 33122694
Drug: M. officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. officinalis extract containing 500 mg of rosmarinic acid (RA) daily
Trial: 39437217
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and Placebo
Trial: 36202695
Drug: CDT or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDT or concurrent care
Trial: 34058616
Drug: Associations between
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Associations between clinical presentation and daily life impact
Trial: 34747997
Drug: Personalized and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized and interactive messages three times a week for 2 weeks; then daily for 2 weeks
Trial: 35246089
Drug: HAP‐peptide suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAP‐peptide suspension with NaOCl pre‐treatment (6.25 wt% HAP and 5 ml P11‐4 peptide, NaOCl 3%)
Trial: 35246089
Drug: P11‐4 peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P11‐4 peptide (5 ml)
Trial: 33165879
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of lidocaine
Trial: 33165879
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg of lidocaine
Trial: 35210504
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (MG)
Trial: 35038429
Drug: Sugemalimab 1200
RxNorm normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab 1200 mg intravenously every 3 weeks for up to 24 months
Trial: 33677616
Drug: 4 h
RxNorm normalized name: Type 4 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 h HDMTX infusion (12 g/m2)
Trial: 33677616
Drug: 12 h
RxNorm normalized name: 12 Hour Cold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 h HDMTX infusion (12 g/m2)
Trial: 33677616
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 4 h and 12 h infusions
Trial: 33196744
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tissue stabilized guided subcision, microfocused ultrasound, and calcium hydroxylapatite injections
Trial: 33196744
Drug: Concomitant microfocused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant microfocused ultrasound and calcium hydroxylapatite injections followed by tissue stabilized guided subcision
Trial: 32066380
Drug: Treatment-as-usual vocational
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-as-usual vocational rehabilitation (TAU‐VR)
Trial: 34318912
Drug: Heat therapy
RxNorm normalized name: CVS Neck Arm & Leg Heat Therapy Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat therapy for 25 minutes, two times (at 1-hour interval)
Trial: 34318912
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy for 25 minutes, two times (at 1-hour interval)
Trial: 34318912
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no heat or cold therapy)
Trial: 35488192
Drug: Sufentanil (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.35 µg/kg)
Trial: 35488192
Drug: Fentanyl (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (3.5 µg/kg)
Trial: 34128721
Drug: DECTA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DECTA with 300 mg of iodine per kilogram by using an optimized threshold
Trial: 34128721
Drug: Conventional DECTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional DECTA with 300 mg of iodine per kilogram using a conventional threshold
Trial: 34128721
Drug: SECTA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SECTA with standard iodine dose (600 mg of iodine per kilogram)
Trial: 37721178
Drug: Glycine diet
RxNorm normalized name: gamma-Glutamyl-S-(benzyl)-cysteinyl-R(-)-phenylglycine diethyl ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycine diet (30 g glycine per 1 kg meat)
Trial: 34450475
Drug: Cabazitaxel (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (25 mg/m2 every 3 weeks)
Trial: 34450475
Drug: Abiraterone (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone (1000 mg/day) or Enzalutamide (160 mg/day)
Trial: 37492920
Drug: Ligelizumab 24
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligelizumab 24 mg
Trial: 36440464
Drug: Ligelizumab 72
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligelizumab 72 mg
Trial: 36440464
Drug: Ligelizumab 240
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ligelizumab 240 mg
Trial: 33165503
Drug: Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Dose (MD) of the vaccine
Trial: 33165503
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) of the vaccine
Trial: 33165503
Drug: Medium Dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Dose (MD) of the vaccine with 28 days interval
Trial: 33165503
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose (HD) of the vaccine with 28 days interval
Trial: 32922524
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac diethylamine 2.32% w/w gel, applied every 12 hours for 7 days before surgery
Trial: 32922524
Drug: Placebo gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel, applied every 12 hours for 7 days before surgery
Trial: 35597980
Drug: rhPTX-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rhPTX-2 treatment (10 mg/kg intravenous infusions on Days 1, 3, and 5 in the first week of each 28-week cycle, then one infusion every 4 weeks up to Week 128)
Trial: 35597980
Drug: rhPTX-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: rhPTX-2 treatment
Trial: 33045376
Drug: Single triangle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single triangle frontalis suspension using ePTFE suture
Trial: 33045376
Drug: Fox pentagon
RxNorm normalized name: meadow foxtail pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fox pentagon frontalis suspension using ePTFE suture
Trial: 36265942
Drug: Low-dose Paclitaxel-Coated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Paclitaxel-Coated Balloon (Ranger)
Trial: 36265942
Drug: High-dose Paclitaxel-Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Paclitaxel-Coated Balloon (IN.PACT)
Trial: 32785210
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rosuvastatin
Trial: 35943745
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal midazolam (0.1 mg/kg)
Trial: 32487131
Drug: Dietary plant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary plant sterols (PS) intervention: 2 daily portions of margarine providing 1 g PS each (2.0 g/day total) for 4 weeks.